Nanoparticles and the immune system: Challenges and opportunities

Nanomedicine

Volumn 11, Issue 20, 2016, Pages 2621-2624

  Grabbe, Stephan ^a   Landfester, Katharina ^b   Schuppan, Detlef ^a   Barz, Matthias ^a   Zentel, Rudolf ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b MAX PLANCK INSTITUTE FOR POLYMER RESEARCH   (Germany)

Author keywords

cancer immunotherapy; control of immunity; immune tolerance; nanoparticular carriers; removal of immune tolerance

Indexed keywords

NANOPARTICLE;

ANTIGEN PRESENTATION; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; HUMAN; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOSTIMULATION; NANOBIOTECHNOLOGY; NANOMEDICINE; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TUMOR ESCAPE; TUMOR MICROENVIRONMENT; IMMUNOTHERAPY; NEOPLASM;

IMMUNE SYSTEM; IMMUNE TOLERANCE; IMMUNOTHERAPY; NANOPARTICLES; NEOPLASMS;

EID: 84990064334     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm-2016-0281     Document Type: Review

References (23)

1. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 392, 245-252 (1998).
2. Tacken PJ, de Vries IJ, Torensma R, Figdor CG. Dendriticcell immunotherapy: from ex vivo loading to in vivo targeting. Nat. Rev. Immunol. 7, 790-802 (2007).
3. Dömling A, Holak TA. Programmed death-1: Therapeutic success after more than 100 years of cancer immunotherapy. angew. Chem. Int. Ed. Engl. 53(9), 2286-2288 (2014).
4. Van Parijs L, Abbas AK. Homeostasis and self-tolerance in the immune system: Turning lymphocytes off, Science 280(5361), 243-248 (1998).
5. Sahin U, Karikó K, Türeci Ö. mRNA-based therapeuticsdeveloping a new class of drugs, Nat. Rev. Drug Discov. 13(10), 759-780 (2014).
6. Hartmann S, Nuhn L, Palitzsch B et al. CpG-loaded multifunctional cationic nanohydrogel particles as selfadjuvanting glycopeptide antitumor vaccines. adv. Healthc. Mater. 4, 522-527 (2015).
7. Kranz LM, Diken M, Haas H et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature 534(7607), 396-401 (2016).
8. Lammers T, Kiessling F, Hennink WE, Storm G. Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J. Control. Release 161, 175-187 (2012).
9. Reddy ST, Rehor A, Schmoekel HG, Hubbell JA, Swartz MA. In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles. J. Control. Release 112(1), 26-34 (2006).
10. Reddy ST, van der Vlies AJ, Simeoni E, O'Neil CP, Swartz MA, Hubbell JA. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat. Biotechnol. 25(10), 1159-1164 (2007).
11. Nuhn L, Vanparijs N, De Beuckelaer A et al. pH-Degradable imidazoquinoline-ligated nanogels for lymph node focused immune activation. Proc. Natl Acad. Sci. USA 113(29), 8098-8103 (2016).
12. Nuhn L, Barz M, Zentel R. New perspectives of HPMAbased copolymers derived by post-polymerization modification (feature). Macromol. Biosci. 14, 607-618 (2014).
13. Klinker K, Barz M. Polypept(o) ides: hybrid systems based on polypeptides and polypeptoids (feature). Macromol. Rapid Comm. 36, 1943-1957 (2015).
14. Kang B, Opatz T, Landfester K, Wurm F. Carbohydrate nanocarriers in biomedical applications: functionalization and construction. Chem. Soc. Rev. 44, 8301-8325 (2015).
15. Fischer K, Schmidt M. Pitfalls and novel applications of particle sizing by dynamic light scattering. Biomaterials 98, 79-91 (2016).
16. Schoettler S, Becker G, Winzen S et al. Protein adsorption is required for stealth effect of poly(ethylene glycol)-and poly(phosphoester)-coated nanocarriers. Nat. Nanotech. 11, 372-377 (2016).
17. Kang B, Okwieka P, Schoettler S et al. Carbohydrate-based nanocarriers exhibiting specific cell targeting with minimum influence from the protein corona. angew. Chem. Int. Ed. Engl. 54, 7436-7440 (2015).
18. Tappertzhofen K, Bednarczyk M, Koynov K, Bros M, Grabbe S, Zentel R. Towards anticancer immunotherapeutics: well-defined polymer-antibody conjugates for selective dendritic cell targeting. Macromol. Biosci. 14, 1444-1457 (2014).
19. Shao K, Singha S, Clemente-Casares X, Tsai S, Yang Y, Santamaria P. Nanoparticle-based immunotherapy for cancer. aCS Nano 9(1), 16-30 (2015).
20. Irvine DJ, Hanson MC, Rakhra K, Tokatlian T. Synthetic nanoparticles for vaccines and immunotherapy. Chem. Rev. 115, 11109-11146 (2015).
21. Lepeltier E, Nuhn L, Lehr CM, Zentel R. Not just for tumor targeting. Unmet medical needs and opportunities for nanomedicine. Nanomedicine 10(20), 3147-3166 (2015).
22. Toth I, Skwarczynski M. The immune system likes nanotechnology. Nanomedicine (Lond.). 9(17), 2607-2609 (2014).
23. Bacher N, Raker V, Hofmann C et al. Interferon-suppresses cAMP to disarm human regulatory T cells. Cancer Res. 73(18), 5647-5656 (2013).